Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 10/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9604236 | 1.00 | GRM2 (0.38) | GRM2IKBKETBK1PDE4BJAK2 | |
| SCHEMBL8513754 | 1.00 | GRM2 (0.38) | GRM2IKBKETBK1PDE4BJAK2 | |
| SCHEMBL9604231 | 0.91 | GRM2 (0.39) | GRM2PDE4BJAK2JAK1TYK2 | |
| SCHEMBL8513148 | 0.91 | GRM2 (0.39) | GRM2PDE4BJAK2JAK1TYK2 | |
| SCHEMBL9604240 | 0.91 | GRM2 (0.39) | GRM2PDE4BJAK2JAK1TYK2 | |
| SCHEMBL9604238 | 0.90 | GRM2 (0.38) | GRM2PDE4BJAK2JAK1TYK2 | |
| SCHEMBL8512419 | 0.90 | GRM2 (0.38) | GRM2PDE4BJAK2JAK1TYK2 | |
| SCHEMBL8512625 | 0.88 | GRM2 (0.42) | GRM2TBK1JAK2 | |
| SCHEMBL8509758 | 0.87 | PDE4D (0.45) | GRM2PDE4BFPR2 | |
| SCHEMBL8509437 | 0.85 | PDE4B (0.42) | GRM2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | GRM2, GRIA2, GRIK2 | GRM2 1/4885IKBKE 2056/4885TBK1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.